Normal densities of 5-HT3 receptor recognition sites in Alzheimer's disease.
The present studies investigate the possible difference in 5-HT3 receptor recognition site density in amygdaloid and hippocampal homogenates from patients with Alzheimer's disease compared with age-matched controls. The 5-HT3 receptor recognition site radioligand [3H]-(S)-zacopride identified a comparable density of specific sites (defined by granisetron 10.0 microM) in tissues obtained from patients with Alzheimer's disease as compared to age-matched controls (amygdala, Bmax 41 +/- 4 and 43 +/- 9; hippocampus, Bmax 59 +/- 9 and 51 +/- 9 fmol mg-3 protein; tissue from Alzheimer's disease patients and age-matched controls, respectively, mean +/- s.e.m., n = 7-8). These results suggest that the density of 5-HT3 receptor recognition sites labelled by [3H]-(S)-zacopride are not altered in the amygdala and hippocampus of patients with Alzheimer's disease.
Barnes
N M
NM
Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford, West Yorkshire.
Costall
B
B
Naylor
R J
RJ
Williams
T J
TJ
Wischik
C M
CM
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology; D000679:Amygdala / Q000378:metabolism / Q000473:pathology; D001549:Benzamides; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D005260:Female; D017829:Granisetron; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007191:Indazoles; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011985:Receptors, Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists
D001549:Benzamides; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D017829:Granisetron; D007191:Indazoles; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; C055971:zacopride